ClinicalTrials.gg
RecruitingNCT06942559BOSS-OCDUpdated Nov 10, 2026

Brain-Oscillation Synchronized Stimulation of the DMPFC

An interventional study of EEG-Triggered Repetitive Transcranial Magnetic Stimulation (rTMS) and Non-EEG Triggered Repetitive Transcranial Magnetic Stimulation (rTMS) in Obsessive Compulsive Disorder (OCD) and Treatment Resistant Obsessive Compulsive Disorder, sponsored by Centre for Addiction and Mental Health. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Nov 10, 2026Eligibility revisedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Obsessive-Compulsive Disorder with a site in Canada — 12 open to participants now, 16 under way, none of them phase 3. Obsessive-Compulsive Disorder · Canada.

Planned enrollment
21st of 47
48 · median 39
Started
2025
with 4 others
No phase
33 of 52
7 open now
Primary completion
2029-01
later than 13 of 15 live
Registered
48th of 52
by date
Lead sponsor
4 of 52
Centre for Addiction and Mental Health

Among the 52 studies in Obsessive-Compulsive Disorder with a site in Canada, this one is the 21st largest by planned enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2025, is one of 33 with no phase, reaches primary completion later than 13 of the 15 other live ones, and was the 48th registered.

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

12 of the 52 studies in Obsessive-Compulsive Disorder with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Obsessive-Compulsive Disorder with a site in Canada, or all of them as a file.
02

Study summary

This trial aims to obtain initial evidence about the clinical efficacy and modulation of neurophysiological markers in obsessive compulsive disorder (OCD) using personalized (i.e., electroencephalography (EEG)-triggered) repetitive transcranial magnetic stimulation (rTMS) as compared to non-personalized (i.e., non-EEG triggered), standard rTMS applied to the dorsomedial prefrontal cortex.

Read the detailed description

This trial uses a prospective, randomized, single-blind study design with two treatment arms at the Centre for Addiction and Mental Health (CAMH) in Toronto, ON, Canada. The study aims to compare the clinical effects of EEG-triggered, personalized rTMS (i.e., experimental arm) in the treatment of OCD to those of non-EEG triggered, non-personalized rTMS (i.e., active-comparator arm). Additionally, the study aims to compare the modulation of neurophysiological (i.e., EEG) markers of OCD between the two arms.

Study treatment will be administered five days per week across a six-week treatment course for a total of 30 sessions. Both rTMS arms will use the same TMS coil, stimulation intensity, number of pulses, and anatomical target (i.e., dorsomedial prefrontal cortex).

Clinical outcomes will be measured using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) with clinical response defined as a ≥30% improvement on the Y-BOCS. The self-reported revised Obsessive Compulsive Inventory (OCI-R) and Clinical Global Impressions - Improvement (CGI-I) scale will also be used. Neurophysiological outcomes will be measured by the change in frontoparietal theta amplitude (i.e., 4-7 Hz) and power of TMS-induced theta oscillations.

03

Conditions studied

  • Obsessive Compulsive Disorder (OCD)
  • Treatment Resistant Obsessive Compulsive Disorder

Keywords

  • Obsessive Compulsive Disorder
  • Treatment Resistant Obsessive Compulsive Disorder
  • Transcranial Magnetic Stimulation
  • Repetitive Transcranial Magnetic Stimulation
  • Electroencephalography
  • Electroencephalography Triggered rTMS
  • EEG-Triggered rTMS
  • OCD
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are 18-65 years old;
  2. Have OCD as a primary disorder, confirmed by a MINI diagnosis of OCD;
  3. Have OCD with treatment resistance as defined by failure of at least a course of cognitive-behavioural therapy or a single trial (≥4 weeks) of an SSRI;
  4. Does not meet criteria for substance use disorder as determined by the MINI (with the exception of nicotine and caffeine);
  5. Have a Y-BOCS score ≥20;
  6. Are fluent in the English language (spoken, written and reading);
  7. Have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening;
  8. Must be deemed to have capacity to provide ;
  9. Must sign and date the informed consent form;
  10. Stated willingness to comply with all study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Have any to TMS as determined by the TASS questionnaire (18);
  2. Have a history of a medical or neurological disorder that affects CNS (such as, traumatic brain injury, stroke, Parkinson);
  3. Are pregnant or breast feeding. TMS is not unsafe in pregnancy and therefore we are not requiring a pregnancy test prior to entry. If patients become pregnant during the study they will not be excluded. We are not including patients who are currently aware of being pregnant as OCD can be affected during the later stages of pregnancy and therefore is a potential confound;
  4. Have history of seizures;
  5. Have any metal implant or dentures;
  6. Have serious or unstable medical condition requiring immediate investigation or treatment (e.g. severe or recent cardiac disease);
  7. Have cardiac pacemaker, cochlear implants, implanted electronic devices or non- electronic metallic implants or other contraindications for TMS;
  8. Taking more than 2mg of lorazepam or equivalent benzodiazepine, or any anticonvulsant medication;
  9. Fulfill MINI criteria for Alcohol Use Disorder;
  10. Have received any ablative neurological procedure (e.g., focused ultrasound).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Personalized, EEG-triggered rTMS

    Device: EEG-Triggered Repetitive Transcranial Magnetic Stimulation (rTMS)

  • Active comparator
    Non-personalized, non-EEG triggered rTMS

    Device: Non-EEG Triggered Repetitive Transcranial Magnetic Stimulation (rTMS)

Interventions

  • DeviceEEG-Triggered Repetitive Transcranial Magnetic Stimulation (rTMS)

    The rTMS intervention will be delivered using the MagPro XP - Orange Edition stimulator and COOL D-B80 coil to the dorsomedial prefrontal cortex 4 cm anterior to the foot hotspot. EEG data will be analyzed in real-time using the bossdevice MEDICAL and TMS pulses will be synchronized to the negative peak of the frontoparietal theta oscillation. 500 consecutive EEG theta-oscillation negative-peak triggered quadruplet bursts with a 5ms inter-pulse-interval will be applied at a median inter-burst interval of 2-3s. The therapeutic intervention consists of 30 sessions of 2000 TMS pulses each for a total duration per treatment session of 15-30 minutes.

    Also known as: Personalized rTMS, EEG-triggered rTMS, Personalized TMS, EEG-triggered TMS

  • DeviceNon-EEG Triggered Repetitive Transcranial Magnetic Stimulation (rTMS)

    The rTMS intervention will be delivered using the MagPro XP - Orange Edition stimulator and COOL D-B80 coil to the dorsomedial prefrontal cortex 4 cm anterior to the foot hotspot. High-frequency rTMS consisting of 50 trains at 20 Hz (2s on, 18s off) will be delivered. The therapeutic intervention consists of 30 sessions of 2000 TMS pulses each for a total duration per treatment session of 15-30 minutes.

    Also known as: Standard rTMS, Standard TMS, rTMS, TMS

06

What researchers measure

Primary outcomes

  1. Yale-Brown Obsessive Compulsive Scale (Y-BOCS)

    The Y-BOCS is used to (a) qualify OCD symptoms using a symptom checklist and (b) assess their severity using a symptom severity rating scale. The checklist allows the participant to identify the thoughts and behaviours that are part of their OCD. The severity scale assesses five dimensions of obsessions and compulsions: time spent or occupied, interference with functioning or relationships, degree of distress, resistance, and control (i.e., success with resistance). The scale ranges from 0-40; a lower score indicates less severe OCD, while a higher score indicates more severe OCD.

    Time frame: From screening to the end of the follow-up period (1-month post-intervention)

Secondary outcomes

  1. Obsessive Compulsive Inventory - Revised (OCI-R)

    The OCI-R is a self-reported 18-item scale that measures symptom severity across six domains of OCD: washing, checking, ordering, neutralizing, obsessing, and hoarding. The scale ranges from 0-72; lower scores indicate less severe OCD (or a subclinical presentation for scores \<21), while higher scores indicate more severe OCD.

    Time frame: From screening to the end of the follow-up period (1-month post-intervention)

  2. Clinical Global Impressions - Improvement (CGI-I) Scale

    The CGI-I is a clinician-determined assessment that rates change in global clinical presentation (i.e., improvement or worsening) from the baseline presentation on a 7-point scale.

    Time frame: From screening to the end of the follow-up period (1-month post-intervention)

  3. Electroencephalography (EEG) Markers of OCD

    1. Amplitude of frontoparietal theta oscillations in the resting EEG before and after single treatment sessions measured in dB 2. the power of TMS-induced oscillations in the theta range throughout the six-week treatment course measured in dB

    Time frame: From screening to the end of the follow-up period (1-week post-intervention)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data from this project may be used for future research by internal and/or external project collaborators upon participant consent.

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2029, 48 months after the start.

Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 48 months is above that.

Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Apr 24, 2025
StartActual
Jan 29, 2025
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
3 inclusion criteria edited, 1 added; 9 exclusion criteria edited, 1 added
What changed in the criteria
Inclusion criteria
  • AddedHave OCD as a primary disorder, confirmed by a MINI diagnosis of OCD;
  • EditedHave OCD as a primary disorder, confirmed by a Mini-International Neuropsychiatric Interview (MINI) diagnosis of OCD, with treatment resistance as defined as aby failure of at least onea course of cognitive-behavioural therapy or a single trial (≥4 weeks) of an SSRI;
  • EditedHave a Y-BOCS score >≥20;
  • EditedAre fluent in the English language (spoken, written, and reading);
Exclusion criteria
  • EditedHave any contraindications to TMS as determined by the Transcranial Magnetic Stimulation Adult Safety ScreenTASS questionnaire (TASS18) questionnaire;
  • EditedHave a history of a medical or neurological disorder that affects the central nervous systemCNS (e.g.such as, traumatic brain injury, stroke, Parkinson's disease);
  • EditedAre pregnant or breast feeding. TMS is not unsafe in pregnancy and therefore the study team iswe are not requiring a pregnancy test prior to entry. If participantspatients become pregnant during the study they will not be excluded. The study team isWe are not including peoplepatients who are currently aware of being pregnant as OCD can be affected during the later stages of pregnancy and therefore is a potential confound;
  • EditedHave a history of seizures;
  • EditedHave any metal implantsimplant or dentures;
  • EditedHave a serious or unstable medical condition requiring immediate investigation or treatment (e.g., severe or recent cardiac disease);
  • EditedHave a cardiac pacemaker, cochlear implants, implanted electronic devices, or non- electronic metallic implants, or other contraindications for rTMSTMS;
  • EditedTakeTaking more than 2mg of lorazepam or equivalent benzodiazepine, or any anticonvulsant medication;
  • EditedFulfill MINI criteria for Alcohol Use Disorder.;
  • AddedHave received any ablative neurological procedure (e.g., focused ultrasound).
Nov 10, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameYale-Brown Obsessive Compulsive Scale (Y-BOCS)From screening to the end of the follow-up period (1 week post-intervention) → From screening to the end of the follow-up period (1-month post-intervention)
Nov 10, 2026
Secondary outcomes
3 time frame changed
What changed in the outcomes
  • Time frameObsessive Compulsive Inventory - Revised (OCI-R)From screening to the end of the follow-up period (1 week post-intervention) → From screening to the end of the follow-up period (1-month post-intervention)
  • Time frameClinical Global Impressions - Improvement (CGI-I) ScaleFrom screening to the end of the follow-up period (1 week post-intervention) → From screening to the end of the follow-up period (1-month post-intervention)
  • Time frameElectroencephalography (EEG) Markers of OCDFrom screening to the end of the follow-up period (1 week post-intervention) → From screening to the end of the follow-up period (1-week post-intervention)
Nov 10, 2026
Contact
Study contact changed: n•••@camh.ca · •••8501→a•••@camh.ca · •••8501. See the current contact
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Eligibility 3 inclusion criteria edited, 1 added; 9 exclusion criteria edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • AddedHave OCD as a primary disorder, confirmed by a MINI diagnosis of OCD;
    • EditedHave OCD as a primary disorder, confirmed by a Mini-International Neuropsychiatric Interview (MINI) diagnosis of OCD, with treatment resistance as defined as aby failure of at least onea course of cognitive-behavioural therapy or a single trial (≥4 weeks) of an SSRI;
    • EditedHave a Y-BOCS score >≥20;
    • EditedAre fluent in the English language (spoken, written, and reading);
    Exclusion criteria
    • EditedHave any contraindications to TMS as determined by the Transcranial Magnetic Stimulation Adult Safety ScreenTASS questionnaire (TASS18) questionnaire;
    • EditedHave a history of a medical or neurological disorder that affects the central nervous systemCNS (e.g.such as, traumatic brain injury, stroke, Parkinson's disease);
    • EditedAre pregnant or breast feeding. TMS is not unsafe in pregnancy and therefore the study team iswe are not requiring a pregnancy test prior to entry. If participantspatients become pregnant during the study they will not be excluded. The study team isWe are not including peoplepatients who are currently aware of being pregnant as OCD can be affected during the later stages of pregnancy and therefore is a potential confound;
    • EditedHave a history of seizures;
    • EditedHave any metal implantsimplant or dentures;
    • EditedHave a serious or unstable medical condition requiring immediate investigation or treatment (e.g., severe or recent cardiac disease);
    • EditedHave a cardiac pacemaker, cochlear implants, implanted electronic devices, or non- electronic metallic implants, or other contraindications for rTMSTMS;
    • EditedTakeTaking more than 2mg of lorazepam or equivalent benzodiazepine, or any anticonvulsant medication;
    • EditedFulfill MINI criteria for Alcohol Use Disorder.;
    • AddedHave received any ablative neurological procedure (e.g., focused ultrasound).
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameYale-Brown Obsessive Compulsive Scale (Y-BOCS)From screening to the end of the follow-up period (1 week post-intervention) → From screening to the end of the follow-up period (1-month post-intervention)
    Secondary outcomes 3 time frame changed
    What changed in the outcomes
    • Time frameObsessive Compulsive Inventory - Revised (OCI-R)From screening to the end of the follow-up period (1 week post-intervention) → From screening to the end of the follow-up period (1-month post-intervention)
    • Time frameClinical Global Impressions - Improvement (CGI-I) ScaleFrom screening to the end of the follow-up period (1 week post-intervention) → From screening to the end of the follow-up period (1-month post-intervention)
    • Time frameElectroencephalography (EEG) Markers of OCDFrom screening to the end of the follow-up period (1 week post-intervention) → From screening to the end of the follow-up period (1-week post-intervention)
    Contact Study contact changed: n•••@camh.ca · •••8501→a•••@camh.ca · •••8501. See the current contact
    + 5 other changes: verification date, oversight details, description, arm descriptions and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06942559
Responsible party
Brigitte Zrenner (Principal Investigator, Centre for Addiction and Mental Health) — Principal investigator
First posted
Apr 24, 2025
Start date
Jan 29, 2025
Primary completion
Jan 2029 (estimated)
Completion
Jan 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Brigitte Zrenner, MD
Contact
brigitte.zrenner@camh.ca
416-535-8501 ext. 34574
Ashley Melichercik, MSc
Contact
ashley.melichercik@camh.ca
416-535-8501 ext. 30899
Brigitte Zrenner, MD
principal investigator · Centre for Addiction and Mental Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion